Skip to Main Content

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)

Conditions

Obesity & Weight Control

Phase III

What is the purpose of this trial?

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks (14 visits). Participants with prediabetes will continue in the extension for another 2 years.

  • Trial with
    Eli Lilly and Company
  • Start Date
    07/22/2020
  • End Date
    02/27/2022
Trial Image

For more information about this study, contact:

Mari-Lynet Knight

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/28/2020
  • Study HIC
    #2000026861